KPRX (Kiora Pharmaceuticals) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KPRX Kiora Pharmaceuticals Inc KPRX
33 GF Score
Price $2.63
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Change In Inventory?

Kiora Pharmaceuticals KPRX +2.33% 33 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Kiora Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Kiora Pharmaceuticals's inventory stayed the same from Dec. 2025 to Mar. 2026 .

Kiora Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Kiora Pharmaceuticals's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Kiora Pharmaceuticals's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kiora Pharmaceuticals  (NAS:KPRX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kiora Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kiora Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kiora Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Change In Inventory Related Terms

Kiora Pharmaceuticals Change In Inventory Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Change In Inventory Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KPRX
33GF Score
Kiora Pharmaceuticals Inc KPRX
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $0.00 Mil mean?
Kiora Pharmaceuticals (KPRX) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Change In Inventory too high?
Kiora Pharmaceuticals' current Change In Inventory is $0.00 Mil. Overall, Kiora Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Change In Inventory compare to PHIO and PBM?
Kiora Pharmaceuticals' Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Change In Inventory of $0.00 Mil. The current Change In Inventory is $0.00 Mil. Kiora Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
33GF Score

Get the complete analysis for KPRX

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price